XTLB

XTL Biopharmaceuticals Share Price

3.50
0.25 (7.69%)
3.50
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
XTL Biopharmaceuticals Ltd XTLB NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.25 7.69% 3.50 04:49:00
Open Price Low Price High Price Close Price Prev Close
3.25
Bid Price Ask Price Spread News
3.39 3.58 0.19 - -
Trades Volume Avg Volume 52 Week Range
12 479 16,975 1.12 - 6.11
Last Trade Time Type Quantity Stock Price Currency
04:37:55 14  3.50 USD

XTL Biopharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 18.00M 5.14M 5.14M  -  - -0.20 -16.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - - -

more financials information »

News XTL Biopharmaceuticals

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

XTLB Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

XTL Biopharmaceuticals Ltd is engaged in the field of healthcare. It is a pharmaceutical manufacturer, with a focus on acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.


Your Recent History
NASDAQ
XTLB
XTL Biopha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.